ROS1 Mutations occur in the ROS1 gene. ROS1 is the tyrosine receptor kinase that creates the protein ROS1. It is commonly involved in the genetic rearrangement of a few different cancers, including Non-small cell lung cancer (NSCLC), gastric cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, and angiosarcoma.
In NSCLC, the ROS1 mutation is present in about 1% of cases. Cancer patients who have the ROS1 mutation could be eligible for targeted treatments in clinical trials. In certain cancers with the ROS1 mutation, standard treatment is not effective.
ROS1 Mutations Clinical Trials
Clinical trials research new ways to treat, diagnose, and prevent cancer. Clinical trials go through 4 total phases to get an FDA approval. This process can take a couple of years, so clinical trials can give patients early access to new therapies and drugs that are being researched. ROS1 mutations clinical trials are currently available for enrollment, most of which are designed to treat NSCLC. There are 43 available clinical trials treating cancers with the ROS1 mutation right now. These clinical trials treat NSCLC, malignant solid tumors, lymphoma, and lung carcinoma.
Targeted therapy is important for patients with the ROS1 mutation because it can locate the specific protein and prevent its division and growth. This is unlike standard treatment, which doesn’t target a specific gene protein.
For patients who are unsure if they have a gene mutation like ROS1 mutations, Next Generation Sequencing (NGS), or genetic testing can be done to find what mutations are present if any. If you are interested in this type of testing, consult with your doctor.
There are a few different treatments that can treat cancers with ROS1 mutations:
- Crizotinib (Xalkori)
Consult with your doctor to see if some of the treatments for ROS1 mutations would work for you. All patients are different, so it is important to understand the best treatment plan for your cancer case.